BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05002569 (Relatlimab in post-resection stage III-IV melanoma): BVCT ex-ante prediction vs. reported outcome

On 19 Feb 2025, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 18 Oct 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05002569
Acronym
RELATIVITY-098
Drug Name
Relatlimab
Drug MoA
anti-LAG3 inhibitor
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
post-resection stage III-IV melanoma
Human Patients
1093
Sponsor
Bristol-Myers Squibb
Phase
Phase 3

Prediction of , index 1932

Prospective Prediction
Prediction Index
1932
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit to nivolumab in OS)
Technical Prediction
FAILURE (statistically insignificant additive clinical benefit to nivolumab in RFS)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
241 days in advance
Readout Data Interpretation
Relatlimab + nivolumab achieved non-superior OS compared with nivolumab alone (HR 1.24 95% CI: 0.90-1.72)
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma
Phase
Phase 3
Status
Terminated
Enrollment
1093
Lead sponsor
Bristol-Myers Squibb
Conditions
Melanoma
Interventions
BIOLOGICAL: Nivolumab; BIOLOGICAL: Nivolumab + Relatlimab Fixed Dose Combination
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2021-10-19
Primary completion
2024-12-16
Completion
2025-04-02
Results first posted
2026-01-08
Primary outcomes
  • Recurrence Free Survival (RFS) (Approximately 27.5 Months)

NCT05002569 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials